Expansion of the U.S. Business Using IPO Proceeds
First written in FY2016. 2 of 4 entries say "Restated". Latest entry: FY2019.
47 other companies' latest entry also says "Restated".
- FY2019RestatedAnnual report
「The company has allocated the funds raised at the time of listing mainly to investments to expand its U.S. business, including promotional activities for the PXB mouse business in the United States, such as a consortium with pharmaceutical companies to validate the usefulness of humanized liver mice, as well as increased staffing at its U.S. subsidiary.」
The company reiterates its policy of allocating listing proceeds to promotional activities in the United States, the consortium and increased staffing at its U.S. subsidiary. - FY2018RestatedAnnual report
「The company has allocated the funds raised at the time of listing mainly to investments to expand its U.S. business, including promotional activities for the PXB mouse business in the United States, such as a consortium with pharmaceutical companies to validate the usefulness of humanized liver mice, as well as increased staffing at its U.S. subsidiary.」
The company reiterates its policy of allocating listing proceeds to the North American consortium, promotional activities and increased staffing at its U.S. subsidiary. - FY2017AdvancedAnnual report
「The company has allocated the funds raised at the time of listing mainly to investments to expand its U.S. business, including promotional activities for the PXB mouse business in the United States, such as a consortium with pharmaceutical companies to validate the usefulness of humanized liver mice, as well as increased staffing at its U.S. subsidiary.」
The company states that, following the previous investment plan, it allocated listing proceeds to promotional activities for its U.S. business, the consortium and increased staffing at its U.S. subsidiary. - FY2016First statedAnnual report
「The company plans to invest the funds raised at the time of listing mainly to expand its U.S. business, including promotional activities for the PXB mouse business in the United States, such as a consortium with pharmaceutical companies to validate the usefulness of humanized liver mice, as well as increasing staff at its U.S. subsidiary.」
The company plans to invest the listing proceeds in the North American consortium, promotional activities and increased staffing at its U.S. subsidiary.